Estrogen and Stroke Risk : The Mechanism of Action
|
|
|
- Kerry Parks
- 5 years ago
- Views:
Transcription
1 Women and Stroke SYMPOSIUM Estrogen and Stroke Risk : The Mechanism of Action KOREAN STROKE SOCIETY _9
2 SYMPOSIUM Women and Stroke 10_
3 Estrogen and Stroke Risk: The Mechanism of Action KOREAN STROKE SOCIETY _11
4 SYMPOSIUM Women and Stroke 12_
5 Estrogen and Stroke Risk: The Mechanism of Action References 1. Barrett-Connor,E., Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture, Circulation, 95 (1997) Hulley,S., Grady,D., Bush,T., Furberg,C., Herrington,D., Riggs,B., and Vittinghoff,E., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group, JAMA, 280 (1998) Rossouw,J.E., Anderson,G.L., Prentice,R.L., LaCroix,A.Z., Kooperberg,C., Stefanick,M.L., Jackson,R.D., Beresford,S.A., Howard,B.V., Johnson,K.C., Kotchen,J.M., and Ockene,J., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA, 288 (2002) Grady,D., Herrington,D., Bittner,V., Blumenthal,R., Davidson,M., Hlatky,M., Hsia,J., Hulley,S., Herd,A., Khan,S., Newby,L.K., Waters,D., Vittinghoff,E., and Wenger,N., Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II), JAMA, 288 (2002) Kuller,L.H., Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative, Arterioscler. Thromb. Vasc. Biol., 23 (2003) Reckelhoff,J.F., Gender differences in the regulation of blood pressure, Hypertension, 37 (2001) Huang,A. and Kaley,G., Gender-specific regulation of cardiovascular function: estrogen as key player, Microcirculation., 11 (2004) Harshfield,G.A., Alpert,B.S., Pulliam,D.A., Somes,G.W., and Wilson,D.K., Ambulatory blood pressure recordings in children and adolescents, Pediatrics, 94 (1994) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial, JAMA, 273 (1995) da Costa,L.S., de Oliveira,M.A., Rubim,V.S., Wajngarten,M., Aldrighi,J.M., Rosano,G.M., Neto,C.D., and Gebara,O.C., Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women, Am. J. Cardiol., 94 (2004) Miller,K.W. and Lane,M.D., Estradiol-induced alteration of very-low-density lipoprotein assembly. Possible competition among apoproteins for incorporation into nascent very-low-density lipoprotein, J. Biol. Chem., 259 (1984) Walsh,B.W., Schiff,I., Rosner,B., Greenberg,L., Ravnikar,V., and Sacks,F.M., Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins, N. Engl. J. Med., 325 (1991) Mackey,R.H., Kuller,L.H., Sutton-Tyrrell,K., Evans,R.W., Holubkov,R., and Matthews,K.A., Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study, Arch. Intern. Med., 165 (2005) Henderson,V.W., Estrogen-containing hormone therapy and Alzheimer s disease risk: understanding discrepant inferences from observational and experimental research, KOREAN STROKE SOCIETY _13
6 SPECIAL LECTURE Neuroscience, 138 (2006) Curb,J.D., Prentice,R.L., Bray,P.F., Langer,R.D., Van Horn,L., Barnabei,V.M., Bloch,M.J., Cyr,M.G., Gass,M., Lepine,L., Rodabough,R.J., Sidney,S., Uwaifo,G.I., and Rosendaal,F.R., Venous thrombosis and conjugated equine estrogen in women without a uterus, Arch. Intern. Med., 166 (2006) Canonico,M., Oger,E., Plu-Bureau, Conard,J., Meyer,G., Levesque,H., Trillot,N., Barrellier,M.T., Wahl,D., Emmerich,J., and Scarabin,P.Y., Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study, Circulation, 115 (2007) Rexrode,K.M. and Manson,J.E., Are some types of hormone therapy safer than others? Lessons from the Estrogen and Thromboembolism Risk study, Circulation, 115 (2007) _
CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
Menopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
Haemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
For more than 50 million American women, and millions
AHA Science Advisory Hormone Replacement Therapy and Cardiovascular Disease A Statement for Healthcare Professionals From the American Heart Association Lori Mosca, MD, PhD; Peter Collins, MD; David M.
WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
RESEARCH. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis
Hormone replacement therapy and risk of in postmenopausal women: systematic review and meta-analysis Marianne Canonico, postdoctoral research fellow, 1,2 Geneviève Plu-Bureau, gynaecologist, 1,3 Gordon
Postmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
SERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
The preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
Estrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
All medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
WHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
WHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services
Natural Hormones Replacement An Evidence and Practice Based Approach
Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS
HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
Cardiovascular Risk During the Menopause
Vascular Disease Prevention, 2009, 6, 103-108 103 Cardiovascular Risk During the Menopause Open Access María Jesús Cancelo 1 and Camil Castelo-Branco 2,* 1 Hospital Universitario de Guadalajara, Universidad
The Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
Menopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women
J MM pissn: 2288-6478, eissn: 2288-6761 Journal of Menopausal Medicine 2015;21:104-111 Original Article Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women Jee-Yeon Lee, Hye
Appendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
HORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
VENOUS THROMBOEMBOLISM
ORIGINAL INVESTIGATION Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus J. David Curb, MD; Ross L. Prentice, PhD; Paul F. Bray, MD; Robert D. Langer, MD, MPH; Linda Van Horn,
How HRT Hurts the Heart
How HRT Hurts the Heart Coronary artery disease (CAD) is a killer and recent studies have come up with evidence that HRT might have a role in increasing CAD among women. Why? Zaheer Lakhani, MD, FRCP For
COMPARED WITH PLACEBO,
IGINAL INVESTIGATION Esterified Estrogen and Conjugated Equine Estrogen and the Risk of Incident Myocardial Infarction and Stroke Rozenn N. Lemaitre, PhD, MPH; Noel S. Weiss, MD, DrPH; Nicholas L. Smith,
Menopausal Hormone Therapy: WHAT WE KNOW NOW
3 hours Continuing Education By Karen Roush, MSN, RN, FNP-BC Menopausal Hormone Therapy: WHAT WE KNOW NOW Nurses need to understand the evidence regarding potential risks and benefits, current recommendations,
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
AusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
Supplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
Ischemic heart disease is the leading cause of
The impact of C-Reactive Protein: A Look at the Most Recent Studies and Trials By Davinder S. Jassal, MD, FRCPC; and Blair O Neill, MD, FRCPC, FACC Ischemic heart disease is the world s leading killer,
CORONARY HEART DISEASE
ORIGINAL CONTRIBUTION Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial Elizabeth Barrett-Connor,
Hormone therapy (HT) is one ABSTRACT WOMEN S HEALTH. Current Status of Postmenopausal Hormone Therapy. Mary S. Beattie, MD
Current Status of Postmenopausal Hormone Therapy Mary S. Beattie, MD ABSTRACT Estrogen therapy, with or without progestins, has been widely prescribed for the treatment of menopausal symptoms. However,
The causal role of elevated serum cholesterol levels in the
From Bench to Bedside Prevention and Treatment of Coronary Heart Disease Who Benefits? John C. LaRosa, MD Abstract Coronary heart disease (CHD) remains a leading cause of morbidity and mortality in the
Potential dangers of hormone replacement therapy in women at high risk
ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department
Postmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
THE WOMEN S HEALTH INITIAtive
ORIGINAL CONTRIBUTION JAMA-EXPRESS Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women s Health Initiative Randomized Controlled Trial Writing
Orals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
Annals of Internal Medicine
2 May 2000 Volume 132 Number 9 Annals of Internal Medicine Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease The Heart and Estrogen/progestin Replacement Study Deborah Grady,
MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Ms. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
HRT. Responding to questions about. The Women s Health Initiative (WHI) is a large, CME Workshop. associated with combined
CME Workshop Responding to questions about HRT By Margaret Burnett, MD, BA(Hon), MA, CCFP, FRCPC The Women s Health Initiative (WHI) is a large, prospective, placebo-controlled trial sponsored by the National
Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
Menopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
Physicians and their women patients have. Assessing benefits and risks of hormone therapy in 2008: New evidence, especially with regard to the heart
HOWARD N. HODIS, MD Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology, Professor of Medicine and Preventive Medicine, Professor of Molecular Pharmacology and Toxicology, Director, Atherosclerosis
Estrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
Imvexxy (estradiol) NEW PRODUCT SLIDESHOW
Imvexxy (estradiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Imvexxy Generic name: Estradiol Pharmacological class: Estrogen Strength and Formulation: 4mcg, 10mcg; vaginal inserts Manufacturer: TherapeuticsMD,
Problems in Postmenopausal Women
Menopausal Management: Where are we in 27? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Marianne Canonico, Geneviève Plu-Bureau, Gordon Lowe, Pierre-Yves Scarabin To
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
LIPOPROTEIN(A)[LP(A)] HAS BEEN
![LIPOPROTEIN(A)[LP(A)] HAS BEEN](/thumbs/74/70824927.jpg "LIPOPROTEIN(A)[LP(A)] HAS BEEN")
ORIGINAL CONTRIBUTION Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause Michael G. Shlipak, MD, MPH Joel A. Simon, MD, MPH Eric Vittinghoff,
Coronary Heart Disease in Women: Is There Any Role for Menopausal Hormone Therapy in Cardiac Protection?
N ovember 24 V olume 8, Issue 9 www.cardiologyrounds.org Coronary Heart Disease in Women: Is There Any Role for Menopausal Hormone Therapy in Cardiac Protection? BY NANETTE K. WENGER, MD, FACC, FAHA, MACP
Hormone therapy for menopausal vasomotor symptoms
Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen
Hormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,
Benton Franklin County Medical Society 31st Annual CME Seminar
Management of Current HT/ET and SERM Recommendations Benton Franklin County Medical Society 31st Annual CME Seminar February 21, 2015 Kennewick, Washington Spokane steoporosis Dr. Lynn Kohlmeier Lynn Kohlmeier,
Bioidentical hormone therapy: Clarifying the misconceptions
CURRENT DRUG THERAPY CME CREDIT EDUCATIONAL OBJECTIVE: Readers will discuss the risks and benefits of hormone therapy with their patients LYNN PATTIMAKIEL, MD, NCMP Department of Internal Medicine, Center
Venous thromboembolism (VTE) is a common disease. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women
Menopause: The Journal of The North American Menopause Society Vol. 18, No. 5, pp. 488/493 DOI: 10.1097/gme.0b013e3181f9f7c3 * 2011 by The North American Menopause Society Hormone therapy and recurrence
ORIGINAL INVESTIGATION. Hormone Replacement Therapy and Associated Risk of Stroke in Postmenopausal Women
ORIGINAL INVESTIGATION Hormone Replacement Therapy and Associated Risk of Stroke in Postmenopausal Women Rozenn N. Lemaitre, PhD, MPH; Susan R. Heckbert, MD, PhD; Bruce M. Psaty, MD, PhD; Nicholas L. Smith,
C-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS
COMPARISON OF C-REACTIVE PROTEIN AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN THE PREDICTION OF FIRST CARDIOVASCULAR EVENTS PAUL M. RIDKER, M.D., NADER RIFAI, PH.D., LYNDA ROSE, M.S., JULIE E. BURING,
Epidemiological and Clinical Aspects of Hormone Therapy
Epidemiological and Clinical Aspects of Hormone Therapy Background Treatment with sex hormones is widely used in Sweden, and has been so for many years. Most women use some kind of sex hormones for various
RETIRED. Clinical use of estrogens and progestogens in
Menopause: The Journal of The North American Menopause Society Vol. 11, No. 6, pp. 589-600 DOI: 10.1097/01.gme.0000145876.76178.dc 2004 The North American Menopause Society Text printed on acid-free paper.
Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone
CLIMACTERIC 2012;15(Suppl 1):11 17 Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone A. O. Department of Endocrinology
HRT in the early menopause: scientific evidence and common perceptions
CLIMACTERIC 2008;11:267 272 Summary of the First IMS Global Summit on menopause-related issues HRT in the early menopause: scientific evidence and common perceptions A. Pines, D. W. Sturdee, M. H. Birkhäuser,
Difference between vagifem and yuvafem
Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone
KAJARIN Pure Reflections of Nature
KAJARIN Pure Reflections of Nature FAQS - General Guidelines What is the dosage of the active ingredients in Kajarin products? 4 Balance has approximately 28.9mg of Progesterone per pump 4 Balance Plus
Effect of Postmenopausal Hormones on Inflammation-Sensitive Proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
Effect of Postmenopausal Hormones on Inflammation-Sensitive Proteins The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study Mary Cushman, MD, MSc; Claudine Legault, PhD; Elizabeth Barrett-Connor,
Answers to Your Questions on Bioidentical Hormone Therapy
Answers to Your Questions on Bioidentical Hormone Therapy Question #1: What is bioidentical hormone therapy? There is no real scientific definition for bioidentical hormones, because this term originated
Outline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
Breast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
Financial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
Publications by Core, Collaborative, BAA, and Ancillary Study* as of 11/5/2013
Publications by Core, Collaborative, BAA, and Ancillary Study* as of 11/5/2013 Study # MS ID Title Reference W1 - CT core analytes on 6% Subsample; quarterly core analytes on QC pools A and B W1, W6 204
Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women
Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women Andrea Decensi, MD; Umberto Omodei, MD; Chris Robertson, PhD; Bernardo Bonanni,
Hormone Replacement Therapy and Coronary Heart Disease
CARDIOLOGY BOARD REVIEW MANUAL PUBLISHING STAFF PRESIDENT, GROUP PUBLISHER Bruce M. White EDITORIAL DIRECTOR Debra Dreger EDITOR Robert Litchkofski ASSISTANT EDITOR Rita E. Gould EXECUTIVE VICE PRESIDENT
RESEARCH. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study
Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study Christel Renoux, fellow, 1 Sophie Dell Aniello, statistician, 1 Edeltraut Garbe, professor, 2 Samy Suissa,
Hormone replacement therapy in postmenopausal women
The American Journal of Surgery 188 (2004) 136 149 Review Hormone replacement therapy in postmenopausal women Edgar D. Staren, M.D., Ph.D., M.B.A.*, Shuab Omer, M.D. Department of Surgery, Medical College
Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament
Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics
Heart. Matters of the. Coronary Artery Disease in Women. Case. By Steven K. Wong, MD, FRCPC. In this article:
Focus on CME at the University of British Columbia Matters of the Heart Coronary Artery Disease in Women By Steven K. Wong, MD, FRCPC In this article: 1.Review of recent data on the presentation and diagnosis
See page 138 OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS
Journal of the American College of Cardiology Vol. 34, No. 1, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00155-2 Hormone
OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS
Journal of the American College of Cardiology Vol. 36, No. 7, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)01007-X Natural
Coronary heart disease (CHD) is the single leading cause of
AHA/ACC Scientific Statement: Consensus Panel Statement Guide to Preventive Cardiology for Women Lori Mosca, MD, PhD, Chair; Scott M. Grundy, MD, PhD; Debra Judelson, MD; Kathleen King, PhD, RN; Marian
Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects
The Oncologist N ews B ulletin NCI All Ireland Cancer Conference Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects DOUGLAS B. MUCHMORE Lilly Research Laboratories,
PERSONAL PERSPECTIVE Rise and fall of hormone therapy in postmenopausal women with cardiovascular disease
Menopause: The Journal of The North American Menopause Society Vol. 11, No. 2, pp. 228 235 DOI: 10.1097/01.GME.0000087980.28957.86 2004 The North American Menopause Society Text printed on acid-free paper.
Premature Menopause : Diagnosis and Management
Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges
Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
Jim Paoletti BS Pharmacy, FAARM, FIACP, Director of Education, P2P
presents Converting Patients from Conventional Pioneering Technologies For to Bioidentical Lifestyle Based Medicine Hormone Therapy with Jim Paoletti BS Pharmacy, FAARM, FIACP, Director of Education, P2P
Υπέρταση στις γυναίκες
Υπέρταση στις γυναίκες Ελένη Τριανταφυλλίδη Διευθύντρια ΕΣΥ Καρδιολογίας Υπεύθυνη Αντιυπερτασικού Ιατρείου Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο ΑΤΤΙΚΟΝ Cardiovascular disease is the Europe